LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
43 hedge funds and large institutions have $55.2M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 7 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
2% less funds holding
Funds holding: 44 → 43 (-1)
4.18% less ownership
Funds ownership: 52.14% → 47.95% (-4.2%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
36% less capital invested
Capital invested by funds: $86M → $55.2M (-$30.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.06M |
| 2 |
SC
Samlyn Capital
New York
|
+$455K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$120K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$107K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$90.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$5.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.58M |
| 3 |
SCM
Sio Capital Management
New York
|
-$906K |
| 4 |
Morgan Stanley
New York
|
-$309K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$136K |
LOGC Hedge Fund Activity: Q1 2020 in Review
43 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2020, worth a combined $55.2M — down 36% from $86M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LOGC and 6 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 11 added.
The largest buyer was JP Morgan Chase, adding an estimated $3.06M. The largest seller was Board of Trustees of The Leland Stanford Junior University, exiting entirely with an estimated $5.3M sold.
- 43 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2020, down from 44 in Q4 2019.
- Funds reported $55.2M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2020, down 36% quarter-over-quarter.
- 6 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2020 and 7 closed out, a net change of -1 holder.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2020 was JP Morgan Chase, an estimated $3.06M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2020 was Board of Trustees of The Leland Stanford Junior University, an estimated $5.3M sold.
Based on aggregated 13F filings for Q1 2020.